SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2024

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

a. Since December 31, 2024, the Company has collected approximately $4.0 million from sales to Pfizer and approximately $2.9 million from sales to Brazil.

b. Since December 31, 2024, the Company sold, in the aggregate 1,223,935 shares of Common Stock under the 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $2.5 million in connection with such sales. As a result of such sales, no shares remain available for sale under the 2023 Sales Agreement and the ATM program thereunder is now complete.

c. Since December 31, 2024, the Company issued 908,000 shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately $2.1 million from such exercises. The warrants expired on March 11, 2025. Accordingly, as of March 12, 2025, no warrants remain outstanding.

d. In January 2025, the Company deregistered Protalix BV in the Netherlands thereby ending its corporate existence.